Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

Angela Dispenzieri; Martha Q. Lacy; S. Vincent Rajkumar; Susan M. Geyer; Thomas E. Witzig; Rafael Fonseca; John A. Lust; Philip R. Greipp; Robert A. Kyle; Morie A. Gertz

doi:10.3109/13506120309041743

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

Angela Dispenzieri, Martha Q. Lacy, S. Vincent Rajkumar, Susan M. Geyer, Thomas E. Witzig, Rafael Fonseca, John A. Lust, Philip R. Greipp, Robert A. Kyle, Morie A. Gertz

Research output: Contribution to journal › Article › peer-review

118 Scopus citations

Abstract

Treatments effective against multiple myeloma may be useful in primary systemic amyloidosis (AL). Thalidomide is active in myeloma. Results of the first 12 patients enrolled on aphase II trial of thalidomide for AL are presented. Progressive edema, cognitive difficulties, and constipation occurred in approximately 75%; dyspnea, dizziness and rash in 50%. Five developed progressive renal insufficiency. Deep venous thrombosis and syncope each occurred in two. Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide.

Original language	English (US)
Pages (from-to)	257-261
Number of pages	5
Journal	Amyloid
Volume	10
Issue number	4
DOIs	https://doi.org/10.3109/13506120309041743
State	Published - Dec 2003

Keywords

Amyloidosis
Multiple myeloma
Thalidomide
Toxicity

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.3109/13506120309041743

Cite this

@article{973a212f3b304151bba90732ba6e50b1,

title = "Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis",

abstract = "Treatments effective against multiple myeloma may be useful in primary systemic amyloidosis (AL). Thalidomide is active in myeloma. Results of the first 12 patients enrolled on aphase II trial of thalidomide for AL are presented. Progressive edema, cognitive difficulties, and constipation occurred in approximately 75%; dyspnea, dizziness and rash in 50%. Five developed progressive renal insufficiency. Deep venous thrombosis and syncope each occurred in two. Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide.",

keywords = "Amyloidosis, Multiple myeloma, Thalidomide, Toxicity",

author = "Angela Dispenzieri and Lacy, {Martha Q.} and Rajkumar, {S. Vincent} and Geyer, {Susan M.} and Witzig, {Thomas E.} and Rafael Fonseca and Lust, {John A.} and Greipp, {Philip R.} and Kyle, {Robert A.} and Gertz, {Morie A.}",

note = "Funding Information: Celgene generously supplied the Drug. Supported by NIH grant CA 91561 and Celgene.",

year = "2003",

month = dec,

doi = "10.3109/13506120309041743",

language = "English (US)",

volume = "10",

pages = "257--261",

journal = "Amyloid",

issn = "1350-6129",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

AU - Dispenzieri, Angela

AU - Lacy, Martha Q.

AU - Rajkumar, S. Vincent

AU - Geyer, Susan M.

AU - Witzig, Thomas E.

AU - Fonseca, Rafael

AU - Lust, John A.

AU - Greipp, Philip R.

AU - Kyle, Robert A.

AU - Gertz, Morie A.

N1 - Funding Information: Celgene generously supplied the Drug. Supported by NIH grant CA 91561 and Celgene.

PY - 2003/12

Y1 - 2003/12

N2 - Treatments effective against multiple myeloma may be useful in primary systemic amyloidosis (AL). Thalidomide is active in myeloma. Results of the first 12 patients enrolled on aphase II trial of thalidomide for AL are presented. Progressive edema, cognitive difficulties, and constipation occurred in approximately 75%; dyspnea, dizziness and rash in 50%. Five developed progressive renal insufficiency. Deep venous thrombosis and syncope each occurred in two. Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide.

AB - Treatments effective against multiple myeloma may be useful in primary systemic amyloidosis (AL). Thalidomide is active in myeloma. Results of the first 12 patients enrolled on aphase II trial of thalidomide for AL are presented. Progressive edema, cognitive difficulties, and constipation occurred in approximately 75%; dyspnea, dizziness and rash in 50%. Five developed progressive renal insufficiency. Deep venous thrombosis and syncope each occurred in two. Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide.

KW - Amyloidosis

KW - Multiple myeloma

KW - Thalidomide

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=1642421878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642421878&partnerID=8YFLogxK

U2 - 10.3109/13506120309041743

DO - 10.3109/13506120309041743

M3 - Article

C2 - 14986485

AN - SCOPUS:1642421878

SN - 1350-6129

VL - 10

SP - 257

EP - 261

JO - Amyloid

JF - Amyloid

IS - 4

ER -

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this